Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Free Report) shares are set to reverse split before the market opens on Tuesday, November 5th. The 1-50 reverse split was announced on Friday, November 1st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 4th.
Qualigen Therapeutics Price Performance
Shares of QLGN remained flat at $0.10 on Friday. 2,658,167 shares of the company traded hands, compared to its average volume of 4,660,945. Qualigen Therapeutics has a 12 month low of $0.08 and a 12 month high of $0.78. The firm has a 50 day simple moving average of $0.16 and a 200 day simple moving average of $0.22.
Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.
See Also
- Five stocks we like better than Qualigen Therapeutics
- Energy and Oil Stocks Explained
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- What is the Shanghai Stock Exchange Composite Index?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Canada Bond Market Holiday: How to Invest and Trade
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.